Schedule F Comes for Federal Grant Makers. What It Means for Merit-Based Research Funding.

The people who decide which science gets funded in America are about to lose their job protections. Under the administration's Schedule Policy/Career rule — the renamed Schedule F — federal employees involved in grant making can be reclassified as at-will workers, stripped of civil service due process rights, and removed without appeal to the Merit Systems Protection Board. The Office of Personnel Management estimates 50,000 federal positions will be affected. The Association of American Medical Colleges says the real number could be four times higher.

At the National Institutes of Health, the National Science Foundation, the Department of Defense, and the Department of Education, that category potentially includes program officers, grant reviewers, advisory council members, and agency leadership — the people whose independent judgment stands between scientific merit and political convenience. Ninety-four percent of the more than 40,500 public comments submitted to OPM opposed the rule. It took effect in March 2026 anyway.

How Merit Review Actually Works

To understand what is at stake, you need to understand how federal research grants are awarded — a process that most applicants experience only from the outside.

When a researcher submits an R01 proposal to the NIH, it enters a peer review system that has operated with remarkable consistency since the mid-1940s. The Center for Scientific Review assigns the application to a study section — a panel of 15 to 25 external scientists with relevant expertise. These reviewers score the proposal on five criteria: significance, investigator qualifications, innovation, approach, and environment. Scores are discussed in a group meeting, calibrated against the full slate of applications, and ranked.

The ranked list then goes to an NIH institute's advisory council — a mix of external scientists and public representatives — which reviews the scores for alignment with the institute's strategic priorities. Only after this two-layer review does a program officer make funding recommendations to institute leadership.

At NSF, the process is similar: external panels of three to five reviewers evaluate proposals, a program officer weighs the reviews and makes a recommendation, and division leadership approves or declines. At every stage, the system is designed to insulate funding decisions from anything except scientific quality and strategic fit.

The people who manage this system — the program officers who run study sections, the grants management specialists who process awards, the advisory council members who provide oversight — are career civil servants. Their independence is not a bureaucratic perk. It is the structural feature that makes merit review credible.

What Reclassification Changes

Schedule Policy/Career converts career civil service positions into a new excepted service category. Employees in reclassified positions become functionally at-will: they can be terminated without the due process protections that career positions carry, and they lose their right to appeal dismissals to the Merit Systems Protection Board.

The administration frames this as democratic accountability. Officials have stated that the policy ensures the ability to implement an agenda "free from antidemocratic, unaccountable bureaucratic resistance." The implication is that career federal employees who exercise independent judgment — including in grant-making decisions — are obstacles to be removed rather than safeguards to be preserved.

For grant-making personnel specifically, the implications cascade through the entire review system.

Program officers gain vulnerability. An NIH program officer who champions a politically inconvenient line of research — climate health effects, gun violence epidemiology, health disparities in minority populations — can now be removed by supervisors who face their own political pressures. The formal review process might remain intact, but the person interpreting its results would serve at the pleasure of political appointees.

Reviewers face chilling effects. External peer reviewers are technically insulated because they are not federal employees. But the program officers who recruit them, manage study sections, and synthesize their findings are now at-will. A reviewer who scores a controversial proposal highly can only influence the outcome if the program officer is willing to carry that recommendation forward. Self-censorship need not be explicit to be effective.

Institutional memory erodes. Senior grants management specialists at NIH and NSF carry decades of knowledge about program histories, legal requirements, and interagency coordination. Replacing them with political loyalists — or simply losing them to the private sector as the job becomes less attractive — degrades the administrative capacity to run a $48.7 billion grant-making operation. The NIH funding slowdown that has already produced a 74 percent drop in new competitive awards is partly a staffing problem. Schedule Policy/Career makes it worse.

The Historical Precedent Is Not Reassuring

This is not the first time the independence of federal science has been tested. In 1973, the Nixon administration attempted to impound funds appropriated by Congress for environmental and social programs, essentially refusing to spend money that had been legally allocated. The Supreme Court struck down the practice in Train v. City of New York (1975), establishing that the executive branch cannot unilaterally override congressional spending directives.

In 2006, the Union of Concerned Scientists documented systematic political interference at federal agencies, including the alteration of scientific findings, the suppression of research results, and the appointment of unqualified individuals to scientific advisory panels. The resulting outcry led to bipartisan scientific integrity policies under the Obama administration.

The current moment combines elements of both precedents. OMB is restricting the release of congressionally appropriated NIH funds — a functional impoundment. And the Schedule F reclassification creates the mechanism for political appointees to influence individual grant-making decisions — a structural weakening of the integrity policies that emerged from the 2006 scandals.

The difference is that the 2026 version has a legal architecture designed to survive judicial review. OPM formally promulgated the rule through notice-and-comment rulemaking. The administration argues it is exercising the president's constitutional authority over the executive branch workforce. A legal challenge has been filed by a coalition of federal employee unions and advocacy groups, but the outcome is uncertain.

Where the Research Community Stands

The reaction from research institutions has been sharp. AAMC warned that the scope could be four times what OPM projects, given the breadth of "policy-influencing" work in medical research. The American Physical Society, the American Chemical Society, and the Federation of American Societies for Experimental Biology have all issued statements opposing the reclassification of grant-making personnel.

University government relations offices are framing this as an institutional risk issue. If grant-making decisions become politically influenced — or even perceived as politically influenced — the entire peer review system loses credibility. International collaborators reconsider partnerships. Industry co-funders question whether NIH's imprimatur still signals scientific quality. The reputational capital that American research institutions have built over eight decades of merit-based funding could erode faster than most administrators realize.

States are not waiting to find out. Following the broader pattern of federal uncertainty, at least a dozen states have introduced or expanded state-level research funding programs in 2026. California, New York, Massachusetts, and Illinois have all increased commitments to health research and science innovation, partly to absorb the impact of federal disruptions. These state programs are not substitutes for NIH-scale funding, but they signal a hedging strategy that did not exist two years ago.

What Grant Seekers Should Do

The structural changes to federal grant making do not require researchers to become political activists — though some will. They do require practical adjustments to funding strategy.

Track agency-level implementation. The Schedule Policy/Career rule authorizes but does not mandate reclassification. Each agency decides which positions to convert. NIH, NSF, and DOD have all declined to specify their plans, but the details will emerge in coming months. Follow your professional societies' tracking efforts — they are monitoring agency filings more closely than any individual researcher can.

Build relationships with program officers now. The program officers currently serving at NIH and NSF carry institutional knowledge that may not survive the reclassification wave. Their guidance on funding priorities, review culture, and proposal strategy is more valuable than ever, precisely because it may not be available indefinitely. Attend program officer sessions at professional conferences. Call them. Ask about upcoming solicitations.

Diversify your funding portfolio. The convergence of the NIH spending freeze, the multiyear forward-funding policy, and the Schedule F reclassification creates compounding uncertainty at a single agency. Researchers whose entire funding base is NIH face correlated risk across all three disruptions. DOE, NSF, DARPA, ARPA-H, and private foundations each have independent governance structures. A portfolio approach spreads risk across institutions with different vulnerability profiles.

Document everything. If you observe changes in review processes, unexplained funding delays, or shifts in programmatic priorities that seem disconnected from scientific merit, document them. Professional societies, congressional offices, and inspector general hotlines all need specific, verifiable examples to build accountability cases. Anecdotes become evidence only when they are recorded.

Engage the appropriations process. Congress appropriated $48.7 billion for NIH and $8.75 billion for NSF. Members who voted for those numbers want to see the money spent as intended. District-specific data about NIH-funded jobs, research programs, and economic impact gives appropriators the ammunition to push back on executive overreach. Your institution's government relations team should have these numbers ready.

The Fundamental Question

At its core, the Schedule F debate is about whether the people who allocate billions of dollars in research funding should be independent professionals or political agents. The merit review system exists because Congress decided, eight decades ago, that the best way to advance science is to let scientists evaluate science. Every subsequent reform — the National Research Service Act, the Bayh-Dole Act, the America COMPETES Act — built on that foundation.

The question now is whether that foundation holds. The legal challenge will take years to resolve. The political dynamics will shift with elections and appointments. But the administrative reality is already changing: at-will grant makers will behave differently than protected career employees, whether or not anyone instructs them to.

For researchers, the practical response is the same regardless of how the legal and political battles play out: reduce dependence on any single funding source, build institutional relationships that survive personnel turnover, and never assume that the system you trained in is the system you will retire in. Tools like Granted can help identify funding opportunities across federal agencies, foundations, and state programs — building the diversified portfolio that the current environment demands.